Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn Henry

Showing results (11-20 of 190) with videos related to

Pageof 19
Sort By:
Oncology (Williston Park, N.Y.)|November 16, 2005
Management of patients with muscle-invasive and metastatic bladder cancerN Lynn Henry, Gary MacVicar, Maha Hussain
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Standard and Genomic Tools for Decision Support in Breast Cancer TreatmentN Lynn Henry, Philippe L Bedard, Angela DeMichele
The Breast Journal|July 6, 2019
Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomyMei Wei, Kathryn A Maurer, N Lynn Henry
JCO Oncology Practice|August 12, 2020
Management of Aromatase Inhibitor-Induced Musculoskeletal SymptomsArjun Gupta, N Lynn Henry, Charles L Loprinzi
Oncology (Williston Park, N.Y.)|December 18, 2008
Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for managementN Lynn Henry, Jon T Giles, Vered Stearns
Breast Cancer Research and Treatment|June 9, 2016
Associations between metabolic syndrome, breast cancer recurrence, and the 21-gene recurrence score assayJeanette Muniz, Kelley M Kidwell, N Lynn Henry
JNCI Cancer Spectrum|April 12, 2021
Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated ArthralgiasPatrick M Schnell, Maryam B Lustberg, N Lynn Henry
Pharmacogenomics|March 28, 2017
Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patientsDaniel L Hertz, N Lynn Henry, James M Rae
Women'S Health (London, England)|October 7, 2009
Adjuvant systemic therapy for elderly women with breast cancerN Lynn Henry, Kathleen M Diehl, Daniel F Hayes
Breast Cancer Research and Treatment|May 20, 2026
Change in practice patterns over time for endocrine therapy and radiation therapy in women with breast cancer age 65 and olderAubrey Stickland, Xueting Tao, Kelley Kidwell, et al.
Pageof 19

Showing results (11-20 of 190) with videos related to

Sort By:
Pageof 19
Oncology (Williston Park, N.Y.)|November 16, 2005
Management of patients with muscle-invasive and metastatic bladder cancerN Lynn Henry, Gary MacVicar, Maha Hussain
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Standard and Genomic Tools for Decision Support in Breast Cancer TreatmentN Lynn Henry, Philippe L Bedard, Angela DeMichele
The Breast Journal|July 6, 2019
Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomyMei Wei, Kathryn A Maurer, N Lynn Henry
JCO Oncology Practice|August 12, 2020
Management of Aromatase Inhibitor-Induced Musculoskeletal SymptomsArjun Gupta, N Lynn Henry, Charles L Loprinzi
Oncology (Williston Park, N.Y.)|December 18, 2008
Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for managementN Lynn Henry, Jon T Giles, Vered Stearns
Breast Cancer Research and Treatment|June 9, 2016
Associations between metabolic syndrome, breast cancer recurrence, and the 21-gene recurrence score assayJeanette Muniz, Kelley M Kidwell, N Lynn Henry
JNCI Cancer Spectrum|April 12, 2021
Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated ArthralgiasPatrick M Schnell, Maryam B Lustberg, N Lynn Henry
Pharmacogenomics|March 28, 2017
Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patientsDaniel L Hertz, N Lynn Henry, James M Rae
Women'S Health (London, England)|October 7, 2009
Adjuvant systemic therapy for elderly women with breast cancerN Lynn Henry, Kathleen M Diehl, Daniel F Hayes
Breast Cancer Research and Treatment|May 20, 2026
Change in practice patterns over time for endocrine therapy and radiation therapy in women with breast cancer age 65 and olderAubrey Stickland, Xueting Tao, Kelley Kidwell, et al.
Pageof 19